As noted earlier, we continue to believe that the additional calculation and reporting of the median payer-specific negotiated charge will result in less administrative burden overall for hospitals than in the absence of the Hospital Price Transparency requirements since hospitals are already required to have this information compiled and the burden associated with that compilation is already assumed
For a more detailed discussion of how this payment reduction was initially implemented, we refer readers to the CY 2009 OPPS/ASC final rule with comment period (73 FR 68769 through 68772)
Athira Pharma's fosgonimeton (ATH-1017), part of the same HGF/c-Met program, failed the primary endpoint of its Phase 2/3 LIFT-AD Alzheimer's trial in September 2024
Optional Add-On: Glutahione: The master antioxidant that supports liver detox, skin health, and post-party recovery
Thyroid dysfunction and semen quality
The b12 patch has been evaluated by the food and drug administration